Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Primary Graft Dysfunction: early-phase trial registry
3 of 3 indexed Primary Graft Dysfunction trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #5,209 of 28,707 conditions by registered trial count.
3 US clinical trials · 3 currently recruiting · #5,209 of 28,707 conditions by registered trial count
Primary Graft Dysfunction: 3 US clinical trials tracked, 3 recruiting.
Primary Graft Dysfunction is the subject of 3 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is University of Pennsylvania, running 2 of these trials.
Enrollment posture brief
Registry condition primary-graft-dysfunction
OPEN 3 | RECR 100% | LATE 0 | EARLY 1 | RANK #5209 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)
Primary Graft Dysfunction lists 3 open slots (100% of 3 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Primary Graft Dysfunction on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Primary Graft Dysfunction is recruiting above its size-band peers.
3 of 3 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
3 total, page 1 of 1
Identifying Genetic Characteristics That Increase Risk of Primary Graft Dysfunction Following Lung Transplantation
University of Pennsylvania
NCT00457847
Risk Factors That Increase the Chance of Developing Primary Graft Dysfunction After Lung Transplantation
University of Pennsylvania
NCT00552357
This Study is Assessing the Safety and Efficacy of Immune Inhibition as a Treatment to Prevent Primary Graft Dysfunction
University of California, San Francisco
NCT06853223
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Primary Graft Dysfunction records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Primary Graft Dysfunction trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Primary Graft Dysfunction page
3 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Primary Graft Dysfunction trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- University of Pennsylvania sponsors the most Primary Graft Dysfunction trials on record, review their full trial history before evaluating a specific study. See University of Pennsylvania's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Primary Graft Dysfunction condition card totals 3 registered trials; most-linked intervention Maraviroc; top US site state Pennsylvania. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.